Hutchison China MediTech Limited Sponsored ADR Stock News

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market co...

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau an...

GSK subsidiary ​GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay ‌a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said ​on Thursday.

— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English —

Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting

Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in combination with AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Tagrisso in patients with a form of non-small ...

— First global Phase III trial to show significant progression-free and overall survival benefits in this setting —